The study found worsening disease in those with thinning in the ganglion cell layer plus inner plexiform layer plus peripapillary retinal nerve fibre layer.
To determine the effectiveness of the Risk of Ambulatory Disability (RoAD) score, study researchers evaluated the prognosis of patients with relapsing-remitting MS.
Study researchers sought address the lacking data on the spatial characteristics of lesions affecting the MLF in patients with MS or stroke, the most common pathophysiologies of internuclear ophthalmoplegia.
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
The objective of this study was to evaluate whether a retinal SD-OCT assessment at baseline is associated with long-term disability worsening in people with MS over 10 years.
There may be numerous risk factors and outcomes associated with SARS-CoV-2 infection in patients with multiple sclerosis.
PoNS is a portable, noninvasive, prescription-only device intended to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
Investigators sought to better understand the pathological correlates associated with increased serum GFAP in the normal appearing white matter of patients with multiple sclerosis.
Study researchers examined whether baseline MRI-markers and demographic and clinical data can help predict cognitive worsening patients with multiple sclerosis.
A team of researchers assessed the Novartis-Oxford Multiple Sclerosis data set to investigate the relationship between age, relapse frequency, and phenotypic presentation of multiple sclerosis.
Vascular comorbidity burden among patients with multiple sclerosis may be associated with neurologic dysfunction and neurodegeneration.
A baseline MRI assessment and subsequent clinical and MRI monitoring during the first 2 years of pediatric multiple sclerosis onset can likely provide insights into 9-year prognosis.
Ponesimod is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
While patients with multiple sclerosis are at an overall low risk for severe COVID-19 infection, concern and fear of infection may impact their adherence to care.
Researchers tested the normalized age-related MS severity score they developed with both a Canadian cohort and a Swedish cohort.
A new classification of cognitive deficits for patients with multiple sclerosis may help define disability, make treatment choices, and tailor cognitive rehabilitation strategies.
A team of researchers conducted a cohort study to provide clinicians more evidence about treatment decisions affecting patients with relapsing-remitting multiple sclerosis.
Study researchers reviewed neuroimaging and neuroimmunological data suggesting that altered reward pathways may play a critical role in the development of fatigue, pain, and depression in patients with MS.
The Kessler Foundation announced its plan to conduct a new study that will assess the effects of ocrelizumab, a disease modifying therapy, on cognitive fatigue in patients with multiple sclerosis.
Patients with multiple sclerosis experience decreased physical and mental quality of life as a result of motor and cognitive fatigue.
Study researchers used source-based morphometry to characterize gray matter atrophy and its 1-year evolution across different multiple sclerosis phenotypes.
A team of researchers investigated the relationships between multiple sclerosis characteristics and therapeutic lag on relapses and disease accumulation in this this patient population.
Researchers investigated prognostic role of cognitive impairment for the conversion of radiologically isolated syndrome to multiple sclerosis.
Researchers examined studies on MS environmental and genetic risk factors to investigate 2- and 3- way interactions between BMI at age 20, Epstein-Barr virus infection, and the Class II DRB1 gene.
Researchers re-evaluated the Expanded Disability Status Scale (EDSS) and its relationship with comorbidities and age in patients with and without MS.
The approval for IM use was based on data from an open-label, crossover study that assessed the bioequivalence of single doses of 125mcg of Plegridy administered as an SC and IM injection.
Researchers investigated the potential of long-term immunotherapy for the prevention of disability accumulation in patients with relapsing-remitting MS.
Study researchers investigated whether neurovascular contact with morphological changes influences the etiology of trigeminal neuralgia secondary to MS.
Researchers sought to evaluate the associations between pacing, fatigue, and physical activity in patients with MS.